|
|
|
|||
|
|
|||||
|
News February 3rd, 2010: Apeiron and GSK sign an exclusive licence agreement for Apeiron’s therapeutic enzyme project APN01 Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).  Apeiron_GSK_Press_Release Apeiron_GSK_Press_Release_dePlease download highresolution photos:
All Photos by Karin Gartner. November 2009 On Nov. 17th, one of our major shareholders, business angel and Chairman of the Supervisory Board, DDr. Manfred Reichl has received the award "Business Angel of the Year". Congratulations! October 2009 We congratulate our collaborator Gavin Oudit MD for receiving an award from the Canadian Cardiovascular Society for the "highly innovative and productive research program" he established with Apeiron. "This work opens new, very promising avenues for the treatment of patients with heart failure. The committee has been highly impressed by the translational nature of Oudit's program, from fundamental molecular advances in our understanding of ACE2 biology to clinical applications." More ... August 2009 Apeiron announces its participation in "Oncotyrol - Center for Personalized Cancer Medicine", an international partnership between academia and industry providing an excellent framework for the development of Apeiron's Cbl-b project. May 2009 Treatment of the first healthy volunteer in a placebo-controlled phase I clinical study with APN01 January 2009 pre-IND meeting with US-FDA (APN01 in heart failure) June 2008 APN01 GMP-batch for first clinical trials ready March 2008 pre-IND meeting with US-FDA (APN01 in ARDS) |
|||||
|
|
|||||
